Cochrane · systematic review · CD007356
Rituximab for rheumatoid arthritis
Lopez‐Olivo, MA, Amezaga Urruela, M, McGahan, L, et al. · Cochrane Database of Systematic Reviews · 2015 · Cochrane Library
MusculoskeletalAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 5 · 71.4%High 2 · 28.6%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Rituximab (2 x 1000 mg) plus methotrexate versus methotrexate monotherapy for rheumatoid arthritis
Population: patients with rheumatoid arthritis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Clinical improvement American College of Rheumatology 50% improvement criteria Analysis 1.2 Rituximab (2 x 1000 mg) plus methotrexate vs methotrexate monotherapy | RR 3.3 [2.3, 4.6] | 4 studies · 1165 participants | Moderate Downgraded: imprecision |
Clinical remission (Disease Activity Score‐28 joint count < 2.6) (Scale from 2 to 10) Analysis 1.7 Rituximab (2 x 1000 mg) plus methotrexate vs methotrexate monotherapy | RR 9.1 [0.76, 108.2] | 2 studies · 834 participants | Moderate Downgraded: risk of bias |
Physical function (HAQ‐DI MCID = ‐0.22) Analysis 1.10 Rituximab (2 x 1000 mg) plus methotrexate vs methotrexate monotherapy | RR 1.6 [1.2, 2.1] | 4 studies · 1161 participants | High |
No radiographic progression in total Genant‐modified Sharp score (range 0 to 290) Analysis 1.21 Rituximab (2 x 1000 mg) plus methotrexate vs methotrexate monotherapy | RR 1.2 [1, 1.4] | 1 study · 476 participants | Moderate Downgraded: imprecision |
Health‐related quality of life Rituximab (2 x 1000 mg) plus methotrexate vs methotrexate monotherapy | RR 2 [1.1, 3.4] | 4 studies · 1526 participants | High |
Discontinuations due to adverse events Analysis 6.3 Rituximab (2 x 1000 mg) plus methotrexate vs methotrexate monotherapy | RR 2.1 [0.88, 4.9] | 5 studies · 1385 participants | Moderate Downgraded: risk of bias |
Serious adverse events Analysis 11.2 Rituximab (2 x 1000 mg) plus methotrexate vs methotrexate monotherapy | RR 1 [0.69, 1.5] | 4 studies · 1280 participants | Moderate Downgraded: risk of bias |